MarketPulse

Rett syndrome

4 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Taysha Gene Therapies to Report Q1 2026 Results, Discuss Clinical Pipeline Progress

Taysha Gene Therapies will report Q1 2026 financial results and discuss TSHA-102 Rett syndrome program progress on May 6, 2026.
TSHAclinical-stagegene therapy
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Taysha Gene Therapies Awards $1.3M in Stock Grants to Four New Employees

Taysha Gene Therapies grants 300,000 RSUs and options to purchase 92,400 shares to four new employees under its 2023 Inducement Plan.
TSHArestricted stock unitsgene therapy
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Taysha Gene Therapies Posts $109M Loss, Advances Rett Syndrome Therapy

Taysha Gene Therapies reported $109M 2025 loss while advancing TSHA-102 gene therapy for Rett syndrome with positive safety data and FDA regulatory alignment through 2028.
TSHAFDA approvalclinical trial
GlobeNewswire Inc.GlobeNewswire Inc.··Proqr Therapeutics N.V.

ProQR Advances Gene Therapy Pipeline as Cash Runway Extends to Mid-2027

ProQR reported €92.4M cash, advanced lead program AX-0810 into Phase 1, and achieved $4.5M in Eli Lilly milestones, projecting runway into mid-2027.
LLYPRQRPhase 1 clinical trialbiotech pipeline